<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Longevity and Rejuvenation Therapies Landscape</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Unity Biotechnology</td>
<td>BCL-xL senolytic</td>
</tr>
<tr>
<td class="label">Grifols/Alkahest</td>
<td>Plasma fractions</td>
</tr>
<tr>
<td class="label">Elevian</td>
<td>GDF11</td>
</tr>
<tr>
<td class="label">Altos Labs</td>
<td>OSKM reprogramming</td>
</tr>
<tr>
<td class="label">Calico/AbbVie</td>
<td>ISR modulation, senolytics</td>
</tr>
<tr>
<td class="label">NewLimit</td>
<td>ML-guided reprogramming</td>
</tr>
<tr>
<td class="label">BioAge Labs</td>
<td>DP1 antagonism</td>
</tr>
<tr>
<td class="label">Retro Biosciences</td>
<td>Autophagy + reprogramming</td>
</tr>
<tr>
<td class="label">TAME Consortium</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Loyal</td>
<td>IGF-1 modulation (canine)</td>
</tr>
<tr>
<td class="label">Disease Stage</td>
<td>Longevity Strategy</td>
</tr>
<tr>
<td class="label">Pre-symptomatic (high risk)</td>
<td>CR mimetics, exercise, NAD+ precursors</td>
</tr>
<tr>
<td class="label">Prodromal (biomarker positive)</td>
<td>Senolytics, autophagy enhancers</td>
</tr>
<tr>
<td class="label">Early clinical</td>
<td>Combination with disease-specific Rx</td>
</tr>
<tr>
<td class="
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Longevity and Rejuvenation Therapies Landscape</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Unity Biotechnology</td>
<td>BCL-xL senolytic</td>
</tr>
<tr>
<td class="label">Grifols/Alkahest</td>
<td>Plasma fractions</td>
</tr>
<tr>
<td class="label">Elevian</td>
<td>GDF11</td>
</tr>
<tr>
<td class="label">Altos Labs</td>
<td>OSKM reprogramming</td>
</tr>
<tr>
<td class="label">Calico/AbbVie</td>
<td>ISR modulation, senolytics</td>
</tr>
<tr>
<td class="label">NewLimit</td>
<td>ML-guided reprogramming</td>
</tr>
<tr>
<td class="label">BioAge Labs</td>
<td>DP1 antagonism</td>
</tr>
<tr>
<td class="label">Retro Biosciences</td>
<td>Autophagy + reprogramming</td>
</tr>
<tr>
<td class="label">TAME Consortium</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Loyal</td>
<td>IGF-1 modulation (canine)</td>
</tr>
<tr>
<td class="label">Disease Stage</td>
<td>Longevity Strategy</td>
</tr>
<tr>
<td class="label">Pre-symptomatic (high risk)</td>
<td>CR mimetics, exercise, NAD+ precursors</td>
</tr>
<tr>
<td class="label">Prodromal (biomarker positive)</td>
<td>Senolytics, autophagy enhancers</td>
</tr>
<tr>
<td class="label">Early clinical</td>
<td>Combination with disease-specific Rx</td>
</tr>
<tr>
<td class="label">Moderate-advanced</td>
<td>Supportive longevity (nutrition, exercise)</td>
</tr>
</table>
The longevity and rejuvenation therapies field has emerged as one of the most dynamic areas in biotechnology, with dozens of companies and academic laboratories pursuing interventions that target the fundamental biological hallmarks of aging. Because aging is the single greatest risk factor for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), [corticobasal degeneration](/diseases/corticobasal-degeneration), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and other neurodegenerative conditions, therapies that slow or reverse biological aging could profoundly alter the trajectory of neurodegeneration. This page surveys the major companies, therapeutic strategies, and mechanisms in the longevity field, with emphasis on their relevance to neurodegenerative disease.
The nine hallmarks of aging — genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication — overlap extensively with the molecular pathology of neurodegeneration[@lopezotin2022][@hou2019]. [Tau](/proteins/tau) hyperphosphorylation, [amyloid-beta](/proteins/amyloid-beta) aggregation, [alpha-synuclein](/proteins/alpha-synuclein) misfolding, and [TDP-43](/proteins/tdp-43) proteinopathy all worsen as the proteostatic and autophagic capacity of aging [neurons](/entities/neurons) declines. The emerging field of geroscience proposes that intervening at the level of aging biology — rather than targeting individual proteinopathies — may provide broader therapeutic benefit[@sierra2016].
Founded: 2022 | HQ: San Diego, CA & Cambridge, UK | Funding: >$3 billion (SoftBank, Jeff Bezos, Yuri Milner)
Altos Labs is the most lavishly funded longevity company in history. Co-founded by Rick Klausner and scientific co-founders including Juan Carlos Izpisua Belmonte, Shinya Yamanaka, and Steve Horvath, it pursues partial cellular reprogramming using [Yamanaka factors](/mechanisms/osk-reprogramming-neurodegeneration) (Oct4, Sox2, Klf4, c-Myc — collectively OSKM). The core insight is that transient, cyclic expression of these transcription factors can reverse epigenetic age — as measured by [DNA methylation](/entities/dna-methylation) clocks — without full dedifferentiation to pluripotency[@ocampo2016]. In landmark work, Ocampo et al. demonstrated that cyclic OSKM induction in progeroid mice extended lifespan by 30% and improved tissue function without tumor formation[@ocampo2016].
Neurodegeneration Relevance: Epigenetic drift is a central feature of aging neurons. DNA methylation changes at [MAPT](/genes/mapt), [APP](/genes/app), and [SNCA](/genes/snca) loci accumulate with age and correlate with disease risk[@horvath2018]. Partial reprogramming could theoretically reset these epigenetic marks, restore youthful gene expression patterns, improve [mitochondrial function](/mechanisms/mitochondrial-dysfunction-neurodegeneration), and re-activate neuronal plasticity pathways. Lu et al. demonstrated that OSK (without c-Myc) delivery via AAV restored vision in aged mice by reversing retinal ganglion cell epigenetic age, providing proof of concept for CNS rejuvenation[@lu2020].
Founded: 2013 | HQ: South San Francisco, CA | Parent: Alphabet/Google | Leadership: Arthur Levinson (CEO), Cynthia Kenyon (VP, Aging Research)
Calico is Alphabet's dedicated aging research subsidiary, with an estimated >$2.5 billion in combined funding from Google and AbbVie (a 2014 partnership). Unlike most longevity startups, Calico takes a fundamental-biology-first approach, investing heavily in model organism studies (C. elegans, mice, naked mole rats) and computational biology before advancing therapeutics. Cynthia Kenyon's discovery that daf-2 (insulin/IGF-1 receptor) mutations double C. elegans lifespan[@kenyon1993] provided foundational evidence that single-gene perturbations can dramatically extend longevity.
Pipeline: Calico's collaboration with AbbVie has produced small-molecule programs targeting: (1) calcineurin-[TFEB](/entities/tfeb) activation for [autophagy](/entities/autophagy) enhancement, (2) ISRIB-related compounds for integrated stress response (ISR) modulation, and (3) novel senolytics. ISRIB is particularly relevant to neurodegeneration — it reverses age-related cognitive decline in mice by resetting translational control at eIF2B[@krukowski2020].
Neurodegeneration Relevance: Calico's insulin/IGF-1 signaling expertise directly intersects with [insulin resistance in Alzheimer's disease](/mechanisms/insulin-signaling-neurodegeneration). Reduced IGF-1 signaling paradoxically extends lifespan while also reducing amyloid and tau pathology in mouse models. Calico's ISRIB-related work could address the dysregulated ISR that drives neuronal loss in [prion diseases](/diseases/prion-diseases), [vanishing white matter disease](/diseases/vanishing-white-matter-disease), and tauopathies including [PSP](/diseases/progressive-supranuclear-palsy)[@krukowski2020].
Founded: 2022 | HQ: San Francisco, CA | Funding: >$400 million (Series B, 2024)
Founded by Coinbase CEO Brian Armstrong, NewLimit uses machine learning to optimize partial reprogramming protocols. The company screens combinatorial libraries of transcription factors and small molecules to identify cocktails that reverse epigenetic age — measured by Horvath and other methylation clocks — without causing dedifferentiation or oncogenic transformation. Their initial programs focus on T cell rejuvenation and hepatocyte aging, with plans to expand to neuronal reprogramming.
Neurodegeneration Relevance: NewLimit's ML-guided approach could identify neuron-specific reprogramming cocktails that avoid the safety concerns of viral OSKM delivery. Partial reprogramming of aged [microglia](/cell-types/microglia-neuroinflammation) or [astrocytes](/entities/astrocytes) could reduce [neuroinflammation](/mechanisms/neuroinflammation) and restore supportive glial function.
Founded: 2017 | HQ: Boston, MA | Co-Founded by: David Sinclair
Life Biosciences emerged from David Sinclair's laboratory at Harvard Medical School, building on his work showing that OSK gene therapy reverses retinal ganglion cell aging and restores vision[@lu2020]. The company has developed proprietary AAV-based partial reprogramming vectors and is advancing programs in optic nerve regeneration and CNS aging.
Neurodegeneration Relevance: Life Biosciences' AAV-OSK platform provides a direct path to CNS epigenetic rejuvenation. The company has published data showing that OSK delivery reverses age-related DNA methylation changes in mouse brain neurons, improves synaptic density, and enhances spatial memory[@lu2020]. If this translates to humans, it could represent a fundamentally new approach to AD and PD — rejuvenating neurons rather than clearing specific aggregates.
Founded: 2011 | HQ: South San Francisco, CA | NASDAQ: UBX
Unity Biotechnology is the leading publicly traded senolytic company. Senescent cells — which have irreversibly exited the cell cycle and secrete a pro-inflammatory cocktail termed the senescence-associated secretory phenotype (SASP) — accumulate in the aging brain and contribute to chronic [neuroinflammation](/mechanisms/neuroinflammation)[@bussian2018]. Unity's pipeline targets anti-apoptotic BCL-2 family proteins that senescent cells depend on for survival.
Pipeline: (1) UBX1325 (foselutoclax) — a BCL-xL inhibitor in Phase 2 for diabetic macular edema; (2) earlier CNS programs targeting senescent astrocytes and microglia. Unity's pivot from its failed UBX0101 (p53-MDM2 inhibitor for osteoarthritis) to BCL-xL-focused programs reflects lessons about target selection.
Neurodegeneration Relevance: Bussian et al. demonstrated that genetic or pharmacological clearance of p16-positive senescent astrocytes and microglia in PS19 tau-transgenic mice reduced [tau](/proteins/tau) hyperphosphorylation, prevented cortical and hippocampal neurodegeneration, and preserved cognitive function[@bussian2018]. This landmark study — published in Nature — established that cellular senescence is not merely a bystander in tauopathy but an active driver. Dasatinib plus quercetin (D+Q), the best-characterized senolytic combination, has entered clinical trials (SToMP-AD) for early Alzheimer's disease[@gonzales2024]. See [Senolytics in Neurodegeneration](/therapeutics/senolytics-neurodegeneration) for detailed coverage.
Founded: 2021 | HQ: Redwood City, CA | Funding: $180 million (Sam Altman)
Retro Biosciences pursues three complementary approaches: (1) autophagy enhancement, (2) [cellular reprogramming](/mechanisms/cellular-reprogramming-neurodegeneration), and (3) plasma-inspired therapies. The company's autophagy program is particularly relevant to neurodegeneration — impaired [macroautophagy](/mechanisms/autophagy-lysosome-neurodegeneration) and [chaperone-mediated autophagy](/mechanisms/chaperone-mediated-autophagy) are among the earliest detectable changes in AD and PD[@rubinsztein2011].
Neurodegeneration Relevance: Neurons are post-mitotic and cannot dilute damaged proteins through cell division, making them uniquely dependent on autophagy for proteostasis. Retro's approach — combining autophagy induction with cellular rejuvenation — could simultaneously enhance clearance of tau tangles, Lewy bodies, and [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates while restoring youthful mitochondrial quality control via [PINK1-Parkin](/mechanisms/pink1-parkin-mitophagy) dependent mitophagy[@rubinsztein2011].
Founded: 2020 | HQ: Mountain View, CA | Focus: mRNA-based reprogramming
Turn Biotechnologies delivers Yamanaka factor mRNAs transiently to achieve controlled, reversible epigenetic rejuvenation. Unlike AAV-based approaches, mRNA delivery is inherently time-limited (degraded within days), providing a built-in safety mechanism against over-reprogramming and tumor formation. The company has demonstrated reversal of Horvath clock age in human fibroblasts and chondrocytes.
Neurodegeneration Relevance: mRNA therapeutics can be formulated in lipid nanoparticles (LNPs) for CNS delivery via intrathecal injection, building on the success of mRNA technology for [antisense oligonucleotide delivery](/mechanisms/antisense-oligonucleotide-therapy-neurodegeneration). Transient mRNA-based reprogramming of astrocytes or oligodendrocytes could rejuvenate glial support without the integration risks of viral vectors.
Founded: 2017 | HQ: Boston, MA
Elevian develops therapeutics based on GDF11 (growth differentiation factor 11) and other circulating factors identified through [heterochronic parabiosis](/mechanisms/parabiosis-young-blood-factors) experiments. Katsimpardi et al. showed that GDF11 restores cerebral vasculature and neurogenesis in aged mice[@katsimpardi2014]. However, the GDF11 field remains controversial — subsequent studies from the Bhatt laboratory challenged some initial claims about GDF11 activity versus the closely related myostatin/GDF8[@egerman2015].
Neurodegeneration Relevance: Parabiosis experiments show that young blood factors can reduce amyloid plaque burden, improve synaptic density, and enhance hippocampal neurogenesis in aged AD model mice. Elevian's approach targets systemic rejuvenation through circulating factors, potentially bypassing the [blood-brain barrier](/mechanisms/blood-brain-barrier-biology) challenge.
Founded: 2014 | Acquired by: Grifols (2020)
Alkahest developed plasma fraction-based therapeutics inspired by Tony Wyss-Coray's Stanford laboratory research showing that young plasma improves cognition in aged mice. Their lead candidate GRF6019 (a specific plasma fraction) completed Phase 2 in mild-moderate Alzheimer's. The related AMBAR trial tested therapeutic plasma exchange (TPE) with albumin replacement in 347 AD patients over 14 months, showing 61% less cognitive decline on ADAS-Cog in moderate-stage patients versus sham[@boada2019].
Neurodegeneration Relevance: The AMBAR results suggest that peripheral [amyloid-beta](/proteins/amyloid-beta) clearance via plasma exchange may provide clinical benefit, supporting the "peripheral sink" hypothesis. Grifols continues developing next-generation plasma fractions enriched for neuroprotective factors.
Founded: 2018 | HQ: San Diego, CA
Rejuvenate Bio uses [AAV gene therapy](/mechanisms/cns-drug-delivery-methods) to deliver combinations of longevity-associated genes. Their multi-gene approach targets several aging hallmarks simultaneously — for example, combining telomerase (TERT), follistatin (FST), and Klotho (KL) in a single vector. In a proof-of-concept study, a three-gene AAV cocktail improved cardiac function, reduced obesity, and extended lifespan in aged mice.
Neurodegeneration Relevance: Klotho is particularly interesting for neurodegeneration. [Klotho](/entities/klotho) overexpression enhances synaptic plasticity and cognitive function in aged mice, and Klotho levels decline in AD and PD brains[@dubal2014]. AAV-mediated Klotho expression in the CNS could provide sustained neuroprotection against tau and amyloid pathology.
Founded: 2015 | HQ: Richmond, CA | NASDAQ: BIOA (2024 IPO)
BioAge Labs uses machine learning and a proprietary longitudinal biobank (>15,000 samples with decades of follow-up) to identify drug targets at the intersection of aging and disease. Their lead candidate azelaprag (BGE-175) is a DP1 receptor antagonist that modulates inflammatory macrophage/microglial polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotype. BioAge's STRIDES Phase 2 trial for obesity was discontinued in late 2024, but the company retains its aging biology platform.
Neurodegeneration Relevance: BioAge's DP1 antagonist mechanism is directly relevant to [microglial activation](/mechanisms/microglial-activation-neurodegeneration) in AD and PD. Shifting microglia from a neurotoxic to neuroprotective state could reduce chronic neuroinflammation without immunosuppression.
Founded: 2018 | HQ: Cambridge, UK
Shift Bioscience uses computational systems biology to model [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) in aging and identify intervention targets. Their platform focuses on mitochondrial-nuclear crosstalk, the mitochondrial [unfolded protein response](/entities/unfolded-protein-response) (UPRmt), and mitochondrial DNA heteroplasmy — all of which change dramatically with age and correlate with neurodegeneration.
Neurodegeneration Relevance: Mitochondrial Complex I deficiency is a hallmark of both PD (substantia nigra) and PSP (subthalamic nucleus, globus pallidus). Shift's computational approach could identify druggable nodes in the mitochondrial quality control network that are specifically relevant to neurodegenerative tauopathies and synucleinopathies.
Founded: 2019 | HQ: San Francisco, CA | Funding: >$125 million
Loyal develops longevity interventions for dogs, using them as both a compassionate application and a translational model for human aging. Their lead program LOY-001 targets IGF-1 signaling in large-breed dogs (which have shorter lifespans correlated with higher IGF-1 levels). In 2024, Loyal received the first-ever FDA "reasonable expectation of effectiveness" determination for a lifespan extension drug.
Neurodegeneration Relevance: Dogs naturally develop age-related cognitive dysfunction syndrome (CDS), a canine analog of AD featuring amyloid-beta accumulation, tau pathology, and progressive cognitive decline[@chapagain2018]. Loyal's large-scale canine aging studies could accelerate understanding of aging-neurodegeneration interactions and provide a translational bridge between rodent models and human trials.
Neurons accumulate epigenetic changes over decades that progressively alter gene expression. DNA methylation "clocks" (Horvath, Hannum, GrimAge) correlate with both biological age and neurodegenerative disease risk[@horvath2018]. Key age-related epigenetic changes in neurons include:
Senescent cells in the brain include astrocytes, microglia, oligodendrocyte precursors (OPCs), and endothelial cells. Their SASP includes IL-1-beta, IL-6, TNF-alpha, and matrix metalloproteinases — all of which exacerbate tau phosphorylation and amyloid toxicity[@bussian2018]. Key pathways:
[Autophagy](/mechanisms/autophagy) — particularly macroautophagy and chaperone-mediated autophagy (CMA) — declines progressively with age. In neurons, this creates a vicious cycle: reduced clearance leads to aggregate accumulation, which further impairs autophagic machinery[@rubinsztein2011]. Key targets for longevity-oriented autophagy enhancement:
The IGF-1/insulin/mTOR nutrient-sensing axis is the most evolutionarily conserved aging pathway. Its inhibition extends lifespan from yeast to primates. The TAME (Targeting Aging with Metformin) trial — the first FDA-approved clinical trial targeting aging as an indication — tests whether metformin delays age-related disease onset including dementia[@barzilai2016]. Other caloric restriction mimetics with neurodegeneration relevance include [resveratrol](/therapeutics/resveratrol-neurodegeneration) (SIRT1 activation) and acarbose (glucose absorption reduction).
[Corticobasal syndrome](/diseases/corticobasal-syndrome) and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) are 4R-tauopathies with aggressive trajectories (median survival 6-9 years). The longevity therapy landscape is particularly relevant because:
See [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) for evidence-scored interventions and [CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan) for implementation guidance.
Most longevity interventions face the [blood-brain barrier](/mechanisms/blood-brain-barrier-biology) challenge. Promising delivery approaches include: intrathecal AAV (for gene therapy-based reprogramming), focused ultrasound [BBB](/entities/blood-brain-barrier) opening (for systemically administered senolytics), and intranasal delivery (for small molecules like rapamycin and spermidine). See [CNS Drug Delivery Methods](/mechanisms/cns-drug-delivery-methods).
Tumor risk from OSKM/OSK expression remains the primary safety concern. Strategies to mitigate this include: (1) using OSK without c-Myc (reduces oncogenic risk >90%); (2) mRNA delivery for self-limiting expression; (3) chemical reprogramming using small molecules instead of transcription factors; (4) cell-type-specific promoters restricting expression to post-mitotic neurons.
No single longevity intervention is likely sufficient. Optimal strategies may combine: senolytics (clear damaged cells) → reprogramming (rejuvenate surviving cells) → autophagy enhancement (maintain proteostasis) → caloric restriction mimetics (sustain metabolic benefits). This sequential approach mirrors the concept of combination therapy in oncology.
Measuring treatment response requires validated aging biomarkers. DNA methylation clocks (GrimAge, DunedinPACE) can now track biological age acceleration with reasonable precision, and blood-based proteomic aging clocks (SomaScan) are entering clinical validation[@belsky2022]. For neurodegeneration-specific applications, CSF and plasma [neurofilament light chain](/proteins/neurofilament-light-chain) (NfL) and [p-tau217](/entities/phospho-tau) may serve as surrogate endpoints linking aging interventions to neuronal health.
Founded: 2021 | HQ: Riyadh, Saudi Arabia | Funding: Up to $1 billion/year
Hevolution Foundation, backed by Saudi Arabia's Public Investment Fund, is the largest funder of aging research globally. Rather than developing drugs directly, Hevolution funds academic and translational research grants targeting the biology of aging, with explicit neurodegeneration programs. Their grants support studies of [rapamycin](/therapeutics/rapamycin-tauopathy) analogs, senolytic combinations, and epigenetic reprogramming across multiple academic centers.
Founded: 2014 | HQ: Hong Kong | Focus: AI drug discovery for aging
Insilico Medicine uses generative AI to design novel small molecules targeting aging pathways. Their platform identified USP1 inhibitors and novel kinase targets with anti-aging properties. The company's AI-designed drug INS018_055 for idiopathic pulmonary fibrosis reached Phase 2, demonstrating the viability of AI-first drug discovery for age-related diseases.
Neurodegeneration Relevance: Insilico has published aging-clock analyses of brain tissue identifying molecular targets that distinguish biological from chronological brain age, potentially revealing druggable nodes for neuroprotection[@zhavoronkov2018].
The Dog Aging Project is a large-scale NIH-funded longitudinal study following >45,000 companion dogs to understand how genetics, environment, and interventions influence aging. The TRIAD trial within this project tests low-dose rapamycin in middle-aged dogs — the largest longevity intervention trial in a mammalian species[@creevy2022]. Results showing improved cardiac function in treated dogs support the translational potential of mTOR inhibition.
Neurodegeneration Relevance: Canine cognitive dysfunction provides a natural model for age-related cognitive decline, and the Dog Aging Project's genomic and phenotypic data could identify aging trajectories predictive of cognitive impairment.
Longevity interventions are not intended to replace disease-specific therapies ([cholinesterase inhibitors](/entities/cholinesterase-inhibitors), [levodopa](/therapeutics/levodopa), anti-amyloid antibodies) but rather to complement them by targeting the underlying aging biology that creates disease vulnerability. A conceptual framework for integration:
The TAME trial (Targeting Aging with Metformin), led by Nir Barzilai, is testing this concept by evaluating whether metformin delays the composite onset of cardiovascular disease, cancer, dementia, and mortality in >3,000 adults aged 65-79[@barzilai2016]. If successful, it would establish aging as a treatable indication and open the regulatory path for other geroscience interventions.
The longevity biotechnology sector has attracted over $10 billion in investment since 2020, driven by high-profile backing from technology entrepreneurs (Jeff Bezos, Sam Altman, Brian Armstrong, Larry Page) and sovereign wealth funds. Key trends:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses:
The following diagram shows the key molecular relationships involving Longevity and Rejuvenation Therapies Landscape discovered through SciDEX knowledge graph analysis: